Scleroderma Therapeutics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2028

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Scleroderma Therapeutics Market, By Drug Class

7.1.  Scleroderma Therapeutics Market, By Drug Class, 2021-2028

7.1.1.    Immunosuppressors

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Phosphodiesterase 5 Inhibitors - PHA

7.1.2.1.        Market Revenue and Forecast (2016-2028)

7.1.3.    Endothelin Receptor Antagonists

7.1.3.1.        Market Revenue and Forecast (2016-2028)

7.1.4.    Prostacyclin Analogues

7.1.4.1.        Market Revenue and Forecast (2016-2028)

7.1.5.    Calcium Channel Blockers

7.1.5.1.        Market Revenue and Forecast (2016-2028)

7.1.6.    Analgesics

7.1.6.1.        Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Scleroderma Therapeutics Market, By Indication

8.1.  Scleroderma Therapeutics Market, By Indication, 2021-2028

8.1.1.    Systemic

8.1.1.1.        Market Revenue and Forecast (2016-2028)

8.1.2.    Localized

8.1.2.1.        Market Revenue and Forecast (2016-2028)

Chapter 9.  Global Scleroderma Therapeutics Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, By Drug Class (2016-2028)

9.1.2.    Market Revenue and Forecast, By Indication (2016-2028)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.1.3.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.1.4.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, By Drug Class (2016-2028)

9.2.2.    Market Revenue and Forecast, By Indication (2016-2028)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.2.3.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.2.4.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.2.5.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.2.6.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, By Drug Class (2016-2028)

9.3.2.    Market Revenue and Forecast, By Indication (2016-2028)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.3.3.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.3.4.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.3.5.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.3.6.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, By Drug Class (2016-2028)

9.4.2.    Market Revenue and Forecast, By Indication (2016-2028)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.4.3.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.4.4.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.4.5.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.4.6.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, By Drug Class (2016-2028)

9.5.2.    Market Revenue and Forecast, By Indication (2016-2028)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.5.3.2.        Market Revenue and Forecast, By Indication (2016-2028)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, By Drug Class (2016-2028)

9.5.4.2.        Market Revenue and Forecast, By Indication (2016-2028)

Chapter 10.  Company Profiles

10.1.              F. Hoffman La-Roche Ltd.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Bristol-Myers Squibb Company

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Celgene Corp.

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              arGentis Pharmaceuticals, LLC

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Bayer AG

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Boehringer Ingelheim International GmbH

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Akashi Therapeutics

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Prometic Life Sciences, Inc.

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Emerald Health Pharmaceuticals

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           Kadmon Holdings, Inc.

10.10.1.               Company Overview

10.10.2.               Product Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

10.11.           Fibrocell Science, Inc.

10.11.1.               Company Overview

10.11.2.               Product Offerings

10.11.3.               Financial Performance

10.11.4.               Recent Initiatives

10.12.           Chemomab

10.12.1.               Company Overview

10.12.2.               Product Offerings

10.12.3.               Financial Performance

10.12.4.               Recent Initiatives

10.13.           Seattle Genetics, Inc.

10.13.1.               Company Overview

10.13.2.               Product Offerings

10.13.3.               Financial Performance

10.13.4.               Recent Initiatives

10.14.           Cytori Therapeutics, Inc.

10.14.1.               Company Overview

10.14.2.               Product Offerings

10.14.3.               Financial Performance

10.14.4.               Recent Initiatives

10.15.           Corbus Pharmaceuticals Holdings, Inc.

10.15.1.               Company Overview

10.15.2.               Product Offerings

10.15.3.               Financial Performance

10.15.4.               Recent Initiatives

10.16.           Genkyotex

10.16.1.               Company Overview

10.16.2.               Product Offerings

10.16.3.               Financial Performance

10.16.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

Glossary of Terms